Poolbeg Pharma PLC (LSE:POLB) Financings
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of new ordinary shares Closed: £3.5M raised · GBX 6 a share · OAK Securities Dealers: OAK Securities (lead) Buyers: Cathal Friel (£250,000 subscription) Insiders: Executive Chair Cathal Friel subscribed a further £250,000 Use of proceeds: Fund the POLB 001 TOPICAL trial and the oral GLP-1 proof-of-concept trial to completion; strengthen partnering position | Sep 29, 2026 | US$4.63M |
| Private placement of new ordinary shares Made bigger: £4.87M · GBX 2.5 a share · Shore Capital +1 Dealers: Shore Capital (lead), Shore Capital Stockbrokers Limited (lead) Buyers: Cathal Friel (4,000,000 new Ordinary Shares, investment of £100,000) Insiders: Executive Chair Cathal Friel subscribed for 4,000,000 new Ordinary Shares, an investment of £100,000 Use of proceeds: Phase 2a trial of POLB 001 for cancer immunotherapy-induced CRS, oral GLP-1 proof-of-concept trial, cash runway into 2027 | Jun 23, 2025 | US$6.56M |
| BookBuild Offer Shares (new ordinary shares) Made bigger: £150,000 · GBX 2.5 a share · Shore Capital +1 Dealers: Shore Capital (lead), Shore Capital Stockbrokers Limited Use of proceeds: Fund POLB 001 Phase 2a trial and oral GLP-1 proof of concept trial, providing runway into 2027 | May 22, 2025 | US$201,316 |